GALT


These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright

Out on Wall Street, one group of stocks divides investors into either fans or critics. Penny stocks, or tickers that trade for less …

Galectin (GALT) Announces Positive Guidance Following FDA Meeting on NASH Cirrhosis Program

Galectin Therapeutics (NASDAQ:GALT) announced positive FDA guidance from a discussion on the clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis. Based …

Galectin Therapeutics Inc (GALT) Springs Up 18% as Illinois Businessman Pours Millions in Credit to Finance NASH Therapy Development

Galectin Therapeutics Inc (NASDAQ:GALT) shares are jumping almost 18% today on the heels of the drug maker walking into a credit line to …

This Analyst Remains Positive on Galectin Therapeutics Inc (GALT) Even as He Slashes Price Target

Roth Capital’s Yasmeen Rahimi still pinpoints almost 30% upside potential for GALT shares following the biotech firm’s failed Phase 2b trial.

Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure

Galectin Therapeutics Inc (NASDAQ:GALT) is crash-landing 35% to the market floor once investors caught word of the biotech firm’s Phase 2b NASH-CX study …

Stock Update (NASDAQ:GALT): Here’s Why Galectin Therapeutics Inc Shares Jumped 44% Today

Galectin Therapeutics Inc (NASDAQ:GALT) investors are overwhelmingly excited today after the drug maker announced its plans to identify a strategic partnership for its galectin-3 …

This Top Analyst Downgrades Galectin Therapeutics (GALT) Following Phase 2 Failure

On Tuesday, Galectin Therapeutics Inc (NASDAQ:GALT) reported that its pipeline investigational drug GR-MD-02, designed to treat liver fibrosis, missed its primary endpoint in …

Stock Update (NASDAQ:GALT): Here’s Why Galectin Therapeutics Inc Shares Are Crashing 40%

Galectin Therapeutics Inc (NASDAQ:GALT) shareholders are having a rough day after the biopharmaceutical company announced disappointing topline results from NASH-FX, its Phase 2a clinical …

Stock Update (NASDAQ:GALT): Galectin Therapeutics Inc Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development

Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Adam …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts